Measures coronavirus: The contact and cooperation with Rotterdam Partners is slightly different. Read more information

Harbour Biomed and Rotterdam broaden and deepen their relationship

07/03/19

From Shanghai to Rotterdam and back again to deliver the best healthcare to patients! Last week a large delegation led by Ahmed Aboutaleb, Mayor of Rotterdam, visited Harbour Biomed at Zhangjiang Hi-Tech Park in Shanghai. Harbour Biomed is a global biotech company developing innovative therapies for cancer and immune-driven diseases. During the visit Harbour BioMed and Erasmus MC signed an MoU to advance next-gen immuno-oncology and immunology drug discovery, and clinical development.

The delegation included representatives from the Consulate General of the Netherlands in Shanghai, Erasmus University Medical Center, the Netherlands Foreign Investment Agency, Rotterdam Partners, InnovationQuarter and several Rotterdam based companies and educational institutions.

Harbour BioMed and Erasmus MC sign MoU

During the celebration of the 40 years sister city relationship, Harbour BioMed and Erasmus MC signed an MoU to advance next-gen immuno-oncology and immunology drug discovery, and clinical development. Harbour Biomed expects to establish laboratory space in Rotterdam to facilitate scientific collaboration with Erasmus MC investigators across multiple departments.

Harbour BioMed has operations and R&D site in Shanghai and Suzhou, China, business operations and an innovation center including research laboratory in Boston, USA, and an antibody platform innovation center in Rotterdam, the Netherlands. Apart from their location in Cambridge Innovation Center in Boston, Harbour Antibodies recently opened their office in Cambridge Innovation Center in Rotterdam.

My favourite venues (0)